A significant risk reduction was found, however, for estrogen receptor–positive disease in breast cancer–specific mortality (HR = 0.75, 95% CI = 0.60 to 0.92; I2 = 0%; P = .9 for heterogeneity). Here, ESR1 is linked to breast carcinoma.